Phase 3 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing and able to give their written agreement to take part in the trial.
- People who are at least 18 years old.
- People who have locally advanced or metastatic non-small cell lung cancer (a type of lung cancer that has spread or cannot be surgically removed).
- People whose cancer has continued to grow or spread after being treated with a specific type of targeted therapy called an EGFR-TKI.
- People whose cancer has a specific gene change (EGFR mutation) along with a particular protein abnormality (MET amplification or overexpression), as confirmed by a central laboratory.
- People who have at least one area of cancer that can be measured using standard imaging guidelines (RECIST 1.1).
- People who are relatively well and able to carry out daily activities, as measured by a standard health scoring tool (ECOG performance status 0 or 1).
- People who are expected to survive for more than 12 weeks.
- People whose blood counts and organ function (such as liver and kidneys) meet the required health levels.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have previously received or are currently receiving any treatment that targets a protein called c-Met.
- People who have previously received chemotherapy given through the bloodstream (systemic chemotherapy).
- People who have needed to take ongoing steroid or immune-suppressing medications by mouth or injection within the 2 weeks before the first dose.
- People who have had a major surgical procedure (other than a diagnostic procedure or biopsy) within the 4 weeks before the first dose, or who are expected to need major surgery during the study.
- People who still have side effects rated grade 2 or higher (using a standard medical grading system) from any previous cancer treatment at the time of starting the trial, with some exceptions for hair loss and a specific type of nerve-related side effect from platinum-based drugs (confirm with trial site).
- People who have cancer that has spread to the lining around the brain, the brainstem, or is pressing on the spinal cord.
- People who have difficulty swallowing or digestive conditions that might affect how oral medication is absorbed.
- People who have a history of a lung condition called interstitial lung disease, lung inflammation caused by drugs or radiation that required steroid treatment, or who currently show signs of active interstitial lung disease.
- People who have previously had a stem cell transplant or a solid organ transplant, or who plan to have one during the study.
- People who have a serious or active infection requiring intravenous antibiotics or hospitalisation, including certain hepatitis B, hepatitis C, HIV, or syphilis infections meeting specific criteria (confirm with trial site).
- People who have serious or uncontrolled heart or blood vessel disease.
- People who are pregnant or currently breastfeeding.
- People who have been diagnosed with another cancer in the last 5 years, except for certain treated skin cancers, a specific type of early bladder cancer, or cervical cancer in situ that has been treated and cured with surgery.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 025 52169999
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free Survival (PFS) by BIRC
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.